stockrowVeracyte, Inc.
VCYT Healthcare Diagnostics & Research
Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.
- Revenue
- +15.1%
- EPS
- +62.5%
- Free cash flow
- −9.63%
Quarter to September 2026, against a year earlier
Follow VCYT
Alert me
Veracyte, Inc. (VCYT) Operating cash flow
Veracyte, Inc.'s operating cash flow for fiscal 2025 was $136.3M, up 81.5% from $75.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was $173.9M. Over the past ten years it has ranged from −$31.6M (fiscal 2021) to $136.3M (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 4 consecutive fiscal years. Veracyte, Inc. ranks 19th of 49 Diagnostics & Research companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $136.3M | 81.51% |
| FY2024 | $75.1M | 69.82% |
| FY2023 | $44.2M | 486.89% |
| FY2022 | $7.5M | — |
| FY2021 | −$31.6M | — |
| FY2020 | −$9.7M | — |
| FY2019 | −$3.2M | — |
| FY2018 | −$13.5M | — |
| FY2017 | −$23.9M | — |
| FY2016 | −$28.0M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $40.3M | (12.15%) |
| Jun 2026 | $45.8M | 30.13% |
| Mar 2026 | $35.2M | (33.03%) |
| Dec 2025 | $52.6M | 17.49% |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| SHC Sotera Health Company compare | $331.6M |
| RDNT RadNet, Inc. compare | $310.1M |
| VCYT Veracyte, Inc. | $173.9M |
| CDNA CareDx, Inc. compare | $69.0M |
| BLLN BillionToOne, Inc. compare | $47.9M |
| NEO NeoGenomics, Inc. compare | $4.3M |
| ADPT Adaptive Biotechnologies Corporation compare | −$4.3M |
| WGS GeneDx Holdings Corp. compare | −$48.7M |
| GRAL GRAIL, Inc. compare | −$306.2M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on VCYT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement